Enhancing and enlarging the European Partnership on Personalised Medicine (EP PerMEd) (Top-up)

Expected Outcome

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• European countries and regions, along with international partners, are engaged in enhanced collaborative research efforts for the development of innovative personalised medicine approaches regarding prevention, diagnosis and treatment.
• Healthcare authorities, policymakers and other stakeholders develop evidence-based strategies and policies for the uptake of personalised medicine in national or regional healthcare systems.
• Health industries, policymakers and other stakeholders have access to efficient measures and investments to allow swift transfer of research and innovation into market.
• Health industries and other stakeholders can accelerate the uptake of personalised medicine through the adoption of innovative business models.
• Healthcare authorities, policymakers and other stakeholders use improved knowledge and understanding of the health and costs benefits of personalised medicine to optimise healthcare and make healthcare systems more sustainable.
• Healthcare providers and professionals improve health outcomes, prevent diseases and maintain population health through the implementation of personalised medicine.
• Stronger and highly connected local/regional ecosystems of stakeholders, including innovators, are in place and facilitate the uptake of successful innovations in personalised medicine, thus improving healthcare outcomes and strengthening European competitiveness.
• Citizens, patients and healthcare professionals have a better knowledge of personalised medicine and are better involved in its implementation.
• Stakeholders cooperate better and establish a network of national and regional knowledge hubs for personalised medicine.

Scope

This topic targets an action under Article 24(2) HE Regulation aiming to add additional activities to existing grant agreements, together with additional partners that would deliver on those activities. The award of a grant to continue the partnership in accordance with this call should be based on a proposal submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and the additional activities and additional partners to be funded by the grant should be subject to an evaluation. Taking into account that the present action is a continuation of the topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and foresees an amendment to an existing grant agreement, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions. Partners from countries recently associated to Horizon Europe from 2024 onwards (2024 included) are particularly welcome. The existing action, the “European Partnership for Personalised Medicine” (EP PerMed) can only reasonably be enhanced and enlarged on the basis of the existing consortium[1], as the co-funded framework established cannot simply be replaced without significant disruption, given the top-quality, long-term expertise and wide coverage of the beneficiaries comprising this consortium.

The additional activities to be performed by applicants under this topic should consist of several of the following:

• Organisation of activities or tools according to their expertise and interests, e.g.:
• Personalised Medicine (PM) Innovation related activities and tools, business and entrepreneur relations and support, case studies and guides.
• PM public health and social care, people’s engagement, activities to support health system’s ability to turn scientific discoveries into new or improved treatments and services, support the scientific community to tackle complex health and social care challenges, international outreach.
• PM and diversity, underrepresented populations, gender aspects, health data and knowledge mobilisation activities, PM and rare diseases.
• PM related genomics, expert and societal exchange on genomics, opportunities by genomics for innovations and economic growth.
• Contribution to the design and implementation of the specific topics and features of the Transnational Joint Calls as of 2026 to which new partners will contribute national commitments.
• Specific, tailored contributions to other EP PerMed calls such as: Fast Track, Venture Creation Programme, Networking, Twinning calls, Call for surveys, Education calls, etc.
• Organisation of specific EP PerMed events, such as in-situ visits (Work Package 5 - WP5), summer schools (WP3/4).
• Contribution to the development and dissemination of strategic documents in additional geographical areas, for example the Strategic Research and Innovation Agenda (SRIA) updates.
• Development and implementation of other new PM tailored activities within the related WPs.

The total indicative budget for the duration of the co-funded partnership is EUR 109.8 million.

[1] Consortium which was awarded the grant under topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine”.